Spark reels in second $15M payment from Pfizer

Written by John George of Philadelphia Business Journal

Spark Therapeutics said Wednesday it has received a second $15 million payment from Pfizer, this one for hitting pre-specified safety and efficacy development milestones for an experimental gene therapy treatment of hemophilia B the company’s are co-developing.

The gene therapy candidate, called SPK-9001, has received breakthrough therapy and orphan product designations from the Food and Drug Administration.

Click here to read the full article.


©2017 PACT All Rights Reserved